Vania Wisdom, Senior Executive Editor at The Lancet, discusses cancer treatment and research in developing countries. Dr. Dana Rathkopf describes the phase 1 data for the androgen receptor ligand-directed degrader in prostate cancer. Dr. Agarwal discusses the CONTACT-02 trial that analyzed the use of cabozantinib in combination with atezolizumab for mCRPC. Dr. Kim Chi discusses the BRCAAway and CONTACT-02 trials presented at ASCO GU 2024. Dr. Himisha Beltran, describes the activity of novel agent HPN328 in neuroendocrine prostate cancer. Neeraj Agarwal describes the results of the phase III CONTACT-02 trial on cabozantinib plus atezolizumab in prostate cancer.
... Karim Fizazi, MD, PhD, joins the show to discuss the phase III TALAPRO-2 trial published in Nature. Thomas Zilli joins the podcast to talk about the controversies surrounding radiotherapy for prostate cancer. Silke Gillessen and Betrand Tombal discuss the questions which will address this issue at APCCC 2024. Silke Gillessen gives an overview of APCCC 2024 taking place in Lugano, Switzerland, in April. The Uromigos close out the year with Tanya Dorff, MD, as she discusses her favorite prostate cancer studies of 2023. Dr. Rahul Aggarwal discusses his recent paper on a phase 1/2 study on Lu-177 with pembrolizumab for mCRPC. Dr. Kevin Kelly discusses the AMG509 phase 1 study of xaluritamig, a bispecific T cell engager, for prostate cancer. Louise Emmett discusses the phase 2 ENZA-p trial presented at ESMO 2023 on enzalutamide and 177Lu-PSMA-617 for mCRPC. Dr. Nick James discusses the optimal patients to undergo radiotherapy for localized prostate cancer. Dr. Michalski discusses brachytherapy techniques in prostate cancer, plus his work on a recent JCO article on the topic. Jim Catto, PhD, FRCS, joins The Uromigos to discuss the 17-year follow-up data from the PROTECT prostate cancer study. Dr. Susan F. Slovin discusses her recent paper that examined abiraterone with and without cabazitaxel for mCRPC. Chana Weinstock, MD joins the podcast to give career advice and answer our questions about the FDA. We're joined by Walter M. Stadler, MD, to discuss how academic papers are accepted and the steps to take when submitting one.